Analysed POLYRIZON LTD (PLRZ:NASDAQ) News Sources
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
27-04-2026
yahoo.com
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
04-05-2026
yahoo.com
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
13-05-2026
yahoo.com
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
08-06-2026
yahoo.com
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
10-06-2026
yahoo.com
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15-06-2026
yahoo.com
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
17-06-2026
yahoo.com
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
29-06-2026
yahoo.com
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
02-07-2026
yahoo.com
What is the current price of POLYRIZON LTD (PLRZ:NASDAQ)?
The current price of POLYRIZON LTD (PLRZ:NASDAQ) is $14.65.
POLYRIZON LTD (PLRZ:NASDAQ) absolute price change since previous trading day?
The absolute price change of POLYRIZON LTD (PLRZ:NASDAQ) since the previous trading day is $0.29.
POLYRIZON LTD (PLRZ:NASDAQ) percentage price change since previous trading day?
The percentage price change of POLYRIZON LTD (PLRZ:NASDAQ) since the previous trading day is 2.0195%.
What is the most recent average sentiment score for POLYRIZON LTD (PLRZ:NASDAQ)?
The most recent average sentiment score for POLYRIZON LTD (PLRZ:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for POLYRIZON LTD (PLRZ:NASDAQ)?
The most recent sentiment for POLYRIZON LTD (PLRZ:NASDAQ) is .
SEC-8K** Filing Available For POLYRIZON LTD (PLRZ:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.